In a multicenter, open-label phase III trial, patients with melanoma to be infused TILs who underwent resection from melanoma lesions have improved progression-free survival compared with ipilimumab [74, 75], and 86% of the patients recruited were resistant to anti-PD1 therapy. This evidence concerns the gene PDCD1 and melanoma.